Clinical Trials Sponsored by Millennium Laboratories

Total 2625 results

Millennium Pharmaceuticals, Inc.

Completed

A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease

Digestive System Disease

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

Advanced Solid Neoplasm

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Multiple Myeloma | Relapsed/Refractory

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

Diabetic Gastroparesis | Idiopathic Gastroparesis

United States, Belgium, Japan, Poland
Millennium Pharmaceuticals, Inc.

Approved for marketing

An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations

Carcinoma, Non-Small-Cell Lung
Millennium Pharmaceuticals, Inc.

Completed

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

United States, Israel, Spain, France, Ireland, Canada, Germany, Czechia, Italy, Netherlands, Belgium, Bulgaria
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors

Neoplasms, Advanced Solid

Netherlands
Millennium Pharmaceuticals, Inc.

Completed

Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB

Lymphoma | Advanced Solid Tumors

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Melanoma | Solid Tumor | Metastatic Melanoma | Neoplasm

United States, United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors

Solid Tumors

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

Obstructive Sleep Apnea

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis

Light-Chain Amyloidosis

United States, Canada, France, Germany, Italy
Millennium Pharmaceuticals, Inc.

Completed

Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States
Millennium Pharmaceuticals, Inc.

Terminated

Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors

Small Cell Lung Cancer | Ovarian Cancer | Advanced Solid Tumors

Japan, Korea, Republic of
Millennium Pharmaceuticals, Inc.

Completed

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Multiple Myeloma | Advanced Solid Tumors

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

Lymphoma | Solid Tumors

United States
Millennium Pharmaceuticals, Inc.

Completed

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas

Advanced Solid Tumors | Lymphomas

Singapore
Millennium Pharmaceuticals, Inc.

Terminated

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Advanced Malignant Solid Tumors

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants

Healthy Participants

United States
Millennium Pharmaceuticals, Inc.

Completed

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Fallopian Tube Cancer | Breast Carcinoma | Ovarian Carcinoma | Peritoneal Cancer

United States
Millennium Pharmaceuticals, Inc.

Completed

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Lymphoma | Nonhematologic Malignancies

United States
Millennium Pharmaceuticals, Inc.

Terminated

MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Recurrent Gastric Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Advanced Gastrointestinal Carcinoma | Recurrent Gastrointestinal Carcinoma

Taiwan, Korea, Republic of, Japan
Oncotherapeutics
Millennium Pharmaceuticals, Inc.

Terminated

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

United States
Millennium Pharmaceuticals, Inc.

Terminated

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Relapsed or Refractory Systemic Light Chain Amyloidosis

United States, Canada, Spain, Israel, France, Australia, Denmark, Germany, Korea, Republic of, Greece, Netherlands, Brazil, Czechia, Italy, United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of Pevonedistat in Adult East Asian Participants

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan, Taiwan, Korea, Republic of
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function

Healthy Volunteers | Hepatic Impairment

United States
Millennium Pharmaceuticals, Inc.

Completed

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

Hematopoietic Stem Cells

United States, Spain, Taiwan, Australia, Canada, Singapore, Korea, Republic of, Mexico, Switzerland, Japan, Germany, Norway, Israel, Russian Federation, Hungary, United Kingdom, Italy, Romania, Brazil, France, Austria, Belgium, Port... and more
Millennium Pharmaceuticals, Inc.

Completed

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

Clear-cell Metastatic Renal Cell Carcinoma

Spain, Czechia, United States, Canada, Italy, United Kingdom, France, Poland
Millennium Pharmaceuticals, Inc.

Completed

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

Poland, Spain, Malaysia, Turkey, Germany, Czechia, Thailand
Millennium Pharmaceuticals, Inc.

Terminated

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors

Nonhematologic Neoplasms, Advanced

Japan
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Withdrawn

Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)

Precursor Cell Lymphoblastic Leukemia-lymphoma

Spain, United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

Advanced Solid Malignancies

United States, Spain
Millennium Pharmaceuticals, Inc.

Completed

A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies

Non-hematologic Malignancy

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

Advanced Solid Tumors, Neoplasms, Advanced Solid

Hungary
Millennium Pharmaceuticals, Inc.

Terminated

TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)

Critical Illness | Enteral Nutrition | Enteral Feeding Intolerance

United States, Canada, Australia, United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Non-hematologic Malignancies

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies | Hematologic Malignancies

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants

Healthy Volunteers

Netherlands
Millennium Pharmaceuticals, Inc.

Completed

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Poland, Greece, Australia, Sweden

3

Subscribe